Advanced Heart Failure & Transplant Program at the University of Wisconsin – Madison is searching for outstanding HF cardiologists to join our academic faculty and expand our clinical and research programs.
Link: https://t.co/UfF7o3ksa2
Excited to recruit for our existing AHFT fellowship @advocatehealth Christ Medical Center in Oak Lawn. ⬆️volume vad and tx program! Accepting applicants.
Come join myself and @SPauwaa@Nikhil15@VQChau20@DrJessP_MD@MarkDLC_MD and many more!
ACGME ID code 1591614048
🚨 MAJOR news in the #ATTR#amyloidosis world! Today the much-anticipated HELIOS-B results were presented @escardio & simultaneously published in @NEJM. The largest ATTR-CM trial published to date, testing #vutrisiran vs. placebo. Bottom line: Huge win for vutrisiran! Lowered CV events and All-Cause mortality in the overall population & as monotherapy. Now, let’s take a deep dive into the results… https://t.co/iCeK5liS2M
A new paradigm for decongestion in acute #HeartFailure. Rapid uptitration of neurohormonal blockade after HF hospitalization is associated with effective, sustainable decongestion and better outcomes. https://t.co/GFXNTGgfeo
#JACC#STRONGHF@ppponikowski@DaniTomasoni_
Out now in @JAMA_current 📜
Donor hearts are tragically scarce and prioritizing the sickest candidates for transplant is essential to save the most lives
We develop and validate the US-Candidate Risk Score (US-CRS), a novel medical urgency score for heart transplantation 🧵 1/
Complex simplification of structural heart with Echo fusion and AI. Within a few years will be Holo lens and 4D with depth perception. Here's a recent example from my lab where the workflow is routine, this is part of what we see on screen during the procedure. #UABStructural
Join us virtually (FREE Registration) or in-person for the 11th Annual Advocate Christ Advanced HF Symposia this Friday November 3rd, featuring keynote by @MkosiborodMD on the intersection of Cardiometabolic health and Heart Failure
@advocatehealth
📎 https://t.co/E4zqH7MSaL
Collaborative effort betw @advocatehealth @AdvocateAurora #WeAreACMC and St Luke’s to study mortality and nonfatal adverse events in non-trial like (NTL) vs trial like (TL) pts undergoing commercial #HeartMate3#LVAD@TheJHLT Open @ISHLT
https://t.co/X9CtRR8iwZ
Pleased to publish the largest single-center study on "Outcomes of Heart Transplant Donation After Circulatory Death" utilizing the Vanderbilt University Heart Transplant Database. No difference in one-year outcomes compared to DBD recipients!
https://t.co/QfYJQ4b0Tf
Pleased to share our SOA review where we attempt to standardize the RHC and highlight the future of hemodynamic assessment including a deep dive into advanced parameters and dynamic testing. @JCardFail@RyanTedfordMD @Brian_Houston12 @BryanSmithMD
https://t.co/qU8qeIu5dX
Big day for patients with ATTR amyloidosis, as the topline results of ATTRIBUTE-CM are positive!
Acoramidis showed significant benefit for the hierarchical composite of all-cause mortality, CV hospitalization, NTproBNP, and 6MW distance.
https://t.co/IKU5iJ5s3G
A must-read for clinicians who treat HF🫀shock, emphasizing best practices:
🔑Early identification (often subtle in SCAI B)
🔑Hemodynamic profiling of shock with PAC
🔑 Hemodynamically-targeted therapy
🔑 Decongestion
🔑 Early MCS
🔗 https://t.co/rOugcJ0Co9
It’s been a long and incredibly rewarding journey. Thankful for all the mentors I’ve met along the way and excited to begin a new chapter! Couldn’t have asked for a better team, @cardiologyacmc is truly world class